S Macherey1, C Kauffmann2, A Heidenreich2, F Doerr3, T Wahlers3, K Hekmat4. 1. Medizinische Fakultät, Universität zu Köln, Joseph-Stelzmann-Straße 20, 50931, Köln, Deutschland. 2. Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universität zu Köln, Kerpener Straße 62, 50931, Köln, Deutschland. 3. Klinik und Poliklinik für Herz- und Thoraxchirurgie, Universität zu Köln, Kerpener Straße 62, 50931, Köln, Deutschland. 4. Klinik und Poliklinik für Herz- und Thoraxchirurgie, Universität zu Köln, Kerpener Straße 62, 50931, Köln, Deutschland. khosro.hekmat@uk-koeln.de.
Abstract
BACKGROUND: In patients with isolated meta- or synchronous pulmonary metastases from renal cell cancer, lung metastasectomy could be an appropriate treatment option after successful treatment of primary cancer. OBJECTIVES: Presentation of lung metastasectomy as a treatment option in patients with pulmonary metastatic renal cell cancer and the postoperative outcome. Description of alternative treatment modalities focusing on "targeted therapies". MATERIALS AND METHODS: Systematical literature research and qualitative analysis of studies on patients undergoing lung metastasectomy after primary nephrectomy published since 01 January 2000. We assessed operative findings, survival data, and prognostic factors. RESULTS: Pulmonary metastasectomy results in a median postmetastasectomy survival of 26-94 months. The 5‑year survival rates vary between 33 and 58%. The patients' prognosis depends on a prolonged disease-free interval and complete resection of all suspected metastases. In particular, number and location of lung metastases should play a minor role for the indication for lung metastasectomy. CONCLUSIONS: Pulmonary metastasectomy should be considered the treatment of choice in selected patients with successfully resected primary cancer showing no evidence of extrapulmonary metastases and having guaranteed operability and complete resection.
BACKGROUND: In patients with isolated meta- or synchronous pulmonary metastases from renal cell cancer, lung metastasectomy could be an appropriate treatment option after successful treatment of primary cancer. OBJECTIVES: Presentation of lung metastasectomy as a treatment option in patients with pulmonary metastatic renal cell cancer and the postoperative outcome. Description of alternative treatment modalities focusing on "targeted therapies". MATERIALS AND METHODS: Systematical literature research and qualitative analysis of studies on patients undergoing lung metastasectomy after primary nephrectomy published since 01 January 2000. We assessed operative findings, survival data, and prognostic factors. RESULTS: Pulmonary metastasectomy results in a median postmetastasectomy survival of 26-94 months. The 5‑year survival rates vary between 33 and 58%. The patients' prognosis depends on a prolonged disease-free interval and complete resection of all suspected metastases. In particular, number and location of lung metastases should play a minor role for the indication for lung metastasectomy. CONCLUSIONS: Pulmonary metastasectomy should be considered the treatment of choice in selected patients with successfully resected primary cancer showing no evidence of extrapulmonary metastases and having guaranteed operability and complete resection.
Entities:
Keywords:
Lung metastases; Metastasectomy; R0-resection; Renal cell cancer
Authors: Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Lancet Oncol Date: 2012-08-08 Impact factor: 41.316
Authors: Sudish C Murthy; Kwhanmien Kim; Thomas W Rice; Jeevanantham Rajeswaran; Ronald Bukowski; Malcolm M DeCamp; Eugene H Blackstone Journal: Ann Thorac Surg Date: 2005-03 Impact factor: 4.330
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Christopher D Jakubowski; Emily A Vertosick; Brian R Untch; Daniel Sjoberg; Elizabeth Wei; Frank L Palmer; Snehal G Patel; Robert J Downey; Vivian E Strong; Paul Russo Journal: J Surg Oncol Date: 2016-06-23 Impact factor: 3.454
Authors: Juliane Hoerner-Rieber; Marciana Duma; Oliver Blanck; Guido Hildebrandt; Andrea Wittig; Fabian Lohaus; Michael Flentje; Frederick Mantel; Robert Krempien; Michael J Eble; Klaus Henning Kahl; Judit Boda-Heggemann; Stefan Rieken; Matthias Guckenberger Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895